# Cortechs.ai

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cortechs-ai

- Industry: Software
- Headquarters: San Diego, US
- Website: www.cortechs.ai
- Latest round: Series C (Nov 20, 2024)
- Investors on record: 2

## About

Cortechs.ai, based in the US, specializes in AI-driven imaging solutions that enhance the diagnosis and monitoring of neurological and oncological diseases, offering advanced products for healthcare providers.Founded in 2001 and headquartered in San Diego, US, Cortechs.ai develops advanced imaging solutions for medical institutions. The company was co-founded by Anders Dale and is currently led by CEO Chris Airriess and Guri Stark. In November 2024, Cortechs.ai raised an undisclosed amount of venture funding led by VILAS Ventures, with participation from Genting Berhad, marking its second deal.Cortechs.ai specializes in advanced AI-powered imaging solutions designed to enhance the diagnosis and monitoring of neurological and oncological diseases. The company offers a suite of products, including NeuroQuant®, which provides precise brain segmentation and volumetric analysis, enabling clinicians to visualize lesions accurately and track volumetric changes over time. Additional offerings include automated software for CT imaging and advanced prostate MRI optimization, aimed at improving diagnostic accuracy and workflow efficiency in medical institutions. These products are utilized by over 1,500 medical institutions across 44 countries, including renowned organizations such as Johns Hopkins Medicine and Cleveland Clinic. The core focus of Cortechs.ai's solutions is to provide enhanced diagnostic insights for practitioners, ultimately leading to better patient outcomes.Cortechs.ai generates revenue through direct partnerships with healthcare institutions that utilize its advanced imaging solutions. The company operates on a subscription model, providing continuous access to its software tools and regular updates. Revenue streams also include one-time licensing fees for its flagship products, such as NeuroQuant® and NeuroAlign CT, along with support and training services offered to clients. The pricing structure is tailored for institutional clients, reflecting the value of the sophisticated imaging capabilities Cortechs.ai provides in clinical settings.In November 2024, Cortechs.ai plans to utilize the recent funding to support its research and development efforts, advance the development of its product range, and increase its market presence. Their strategy includes designing new products aimed at enhancing diagnostic capabilities, and they are targeting expansion into additional global markets to broaden their reach and impact in the medical imaging industry.

## Funding rounds

- Series C, Nov 20, 2024 — Genting Berhad, S-Curve Partners

## Investors

- Genting Berhad — Series C
- S-Curve Partners (https://capitalatlas.ai/funds/s-curve-partners) — Series C